ATE189697T1 - Die hocheffiziente herstellung und isolierung von viruspartikeln - Google Patents

Die hocheffiziente herstellung und isolierung von viruspartikeln

Info

Publication number
ATE189697T1
ATE189697T1 AT95914170T AT95914170T ATE189697T1 AT E189697 T1 ATE189697 T1 AT E189697T1 AT 95914170 T AT95914170 T AT 95914170T AT 95914170 T AT95914170 T AT 95914170T AT E189697 T1 ATE189697 T1 AT E189697T1
Authority
AT
Austria
Prior art keywords
exchange resin
isolation
cells
highly efficient
virus particles
Prior art date
Application number
AT95914170T
Other languages
English (en)
Inventor
Christopher P Prior
David M Weber
Richard S Gore
James J Harter
Michael E Hrinda
Jonathan J Mitschelen
Thomas W Irish
Pierre M Bay
George C Tarr
Original Assignee
Immune Response Corp Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immune Response Corp Inc filed Critical Immune Response Corp Inc
Application granted granted Critical
Publication of ATE189697T1 publication Critical patent/ATE189697T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT95914170T 1994-03-22 1995-03-22 Die hocheffiziente herstellung und isolierung von viruspartikeln ATE189697T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21583394A 1994-03-22 1994-03-22
PCT/US1995/003668 WO1995025789A1 (en) 1994-03-22 1995-03-22 Highly efficient production and isolation of viral particles

Publications (1)

Publication Number Publication Date
ATE189697T1 true ATE189697T1 (de) 2000-02-15

Family

ID=22804586

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95914170T ATE189697T1 (de) 1994-03-22 1995-03-22 Die hocheffiziente herstellung und isolierung von viruspartikeln

Country Status (12)

Country Link
US (2) US5661023A (de)
EP (1) EP0751988B1 (de)
JP (1) JP3313117B2 (de)
AT (1) ATE189697T1 (de)
AU (1) AU2127395A (de)
CA (1) CA2186034C (de)
DE (1) DE69515028T2 (de)
DK (1) DK0751988T3 (de)
ES (1) ES2141929T3 (de)
GR (1) GR3033268T3 (de)
PT (1) PT751988E (de)
WO (1) WO1995025789A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0751988B1 (de) * 1994-03-22 2000-02-09 The Immune Response Corporation Die hocheffiziente herstellung und isolierung von viruspartikeln
FR2750433B1 (fr) * 1996-07-01 1998-08-14 Rhone Poulenc Rorer Sa Procede de production d'adenovirus recombinants
CZ438398A3 (cs) * 1996-07-01 1999-03-17 Rhone-Poulenc Rorer S. A. Způsob přípravy rekombinantních adenovirů
WO1998022588A2 (en) 1996-11-20 1998-05-28 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
DK1944362T3 (en) * 1997-09-05 2016-01-25 Genzyme Corp Fremgangsmåder til fremstilling af hjælpevirusfri præparater med høj titer af rekombinante AAV-vektorer
WO1999034810A1 (en) * 1998-01-12 1999-07-15 Her Majesty In Right Of Canada As Represented By The Minister Of Agriculture And Agri-Food Canada A process for the isolation, recovery and purification of non-polar extractives
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
DE10010342A1 (de) * 2000-03-06 2001-09-20 Merck Patent Gmbh Verfahren zur Abreicherung von Endotoxinen
SE0001132D0 (sv) * 2000-03-29 2000-03-29 Cavidi Tech Ab Method of concentrating and recovering a viral enzyme activity from biological samples
WO2001085928A1 (en) * 2000-05-10 2001-11-15 Mitsubishi Pharma Corporation Method of preparing virus vector
WO2002044394A2 (en) 2000-11-29 2002-06-06 University Of Southern California Targetet retoviral vectors for cancer immunotherapy
MXPA03007141A (es) * 2001-02-11 2003-11-18 Aquanova Ger Solubilisate Tech Procedimiento para la preparacion de un concentrado de ingredientes activos, y un concentrado de ingredientes activos.
DE10137515A1 (de) * 2001-07-26 2003-02-13 Diagnostikforschung Inst Verfahren zur Herstellung pharmazeutischer Zubereitungen
US20030031626A1 (en) * 2001-07-26 2003-02-13 Thomas Rheinlander Process for the production of pharmaceutical preparations
US20090123428A1 (en) * 2003-04-21 2009-05-14 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
US20070178066A1 (en) 2003-04-21 2007-08-02 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
ES2366617T3 (es) * 2003-04-21 2011-10-21 Epeius Biotechnologies Corporation Métodos y composiciones para el tratamiento de transtornos.
CA2586107A1 (en) 2004-11-03 2006-05-18 Introgen Therapeutics Inc. A novel method for the production and purification of adenoviral vectors
WO2009153563A1 (en) 2008-06-18 2009-12-23 Oxford Biomedica (Uk) Limited Virus purification
JP2013523175A (ja) 2010-04-14 2013-06-17 イーエムディー・ミリポア・コーポレーション 高力価、高純度のウイルスストックの作製方法及びその使用方法
DE102010046817A1 (de) * 2010-09-28 2012-03-29 Sartorius Stedim Biotech Gmbh Verfahren zur Abtrennung von Viren aus einem Kontaminanten enthaltenden flüssigen Medium
EP3219313B1 (de) 2011-04-18 2020-10-28 National Center of Neurology and Psychiatry Arzneimittelabgabepartikel und verfahren zur herstellung davon
MY195756A (en) 2012-09-17 2023-02-09 Grace W R & Co Functionalized Particulate Support Material and Methods of Making and Using the Same
IN2015DN02055A (de) 2012-09-17 2015-08-14 Grace W R & Co
EP3094390B1 (de) 2014-01-16 2021-07-07 W.R. Grace & CO. - CONN. Affinitätschromatographiemedien und chromatographievorrichtungen
EP3137209B1 (de) 2014-05-02 2022-10-05 W.R. Grace & CO. - CONN. Funktionalisiertes trägermaterial und verfahren zur herstellung und verwendung eines funktionalisierten trägermaterials
SG10201911134QA (en) 2015-06-05 2020-01-30 Grace W R & Co Adsorbent bioprocessing clarification agents and methods of making and using the same
CN111417713B (zh) 2017-11-22 2024-04-26 康宁股份有限公司 灌注生物反应器系统及灌注细胞培养方法
US11028124B2 (en) 2018-05-07 2021-06-08 Repligen Corporation Methods, devices and systems for 3-stage filtration
WO2020214676A1 (en) * 2019-04-15 2020-10-22 Children's Hospital Medical Center Viral vector manufacturing methods

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3509070A (en) * 1968-06-13 1970-04-28 American Home Prod Adsorbent for chromatographic purification of virus
US3655509A (en) * 1969-05-29 1972-04-11 Monsanto Co Process for the separation of virus from non-viral proteins
US3925152A (en) * 1971-06-18 1975-12-09 Exploaterings Ab Tbf Virus separation
US4647773A (en) * 1984-04-23 1987-03-03 The United States Of America As Represented By The Department Of Health And Human Services Method of continuous production of retroviruses (HTLV-III) from patients with AIDS and pre-AIDS
JPS6147185A (ja) * 1984-08-09 1986-03-07 Chemo Sero Therapeut Res Inst 日本脳炎ウイルスの精製方法
JPS6151571A (ja) * 1984-08-21 1986-03-14 Nippon Seibutsu Kagaku Kenkyusho オ−エスキ−病診断用抗原の単離・精製法
JPH0720880B2 (ja) * 1987-06-10 1995-03-08 ジ イミューン リスポンス コーポレーション，インコーポレーテッド レトロウイルス疾患の予防および治療
NZ225583A (en) * 1987-08-06 1991-07-26 Merck & Co Inc Process for purifying hepatitis a virions (hav)
CA2077753C (en) * 1990-03-09 2000-02-29 Nancy L. Haigwood Purified gp120 composition retaining natural conformation
FR2661834B1 (fr) * 1990-05-09 1995-01-27 Merieux Inst Procede de fabrication d'immunogenes de retrovirus et de vaccins contre les infections retrovirales, notamment hiv, et immunogenes et vaccins obtenus.
CA2098510A1 (en) * 1990-12-13 1992-06-14 Kenneth W. Culver Sustained and continuous production of high titers of recombinant viral vectors and transduced target cells for use in gene therapy
EP0751988B1 (de) * 1994-03-22 2000-02-09 The Immune Response Corporation Die hocheffiziente herstellung und isolierung von viruspartikeln
JPH08195877A (ja) * 1995-01-18 1996-07-30 Canon Inc イメージセンサと画像処理回路

Also Published As

Publication number Publication date
DK0751988T3 (da) 2000-06-26
JP3313117B2 (ja) 2002-08-12
AU2127395A (en) 1995-10-09
DE69515028T2 (de) 2000-06-29
EP0751988A1 (de) 1997-01-08
PT751988E (pt) 2000-05-31
CA2186034A1 (en) 1995-09-28
EP0751988A4 (de) 1997-11-12
ES2141929T3 (es) 2000-04-01
CA2186034C (en) 2002-11-26
DE69515028D1 (de) 2000-03-16
US5661023A (en) 1997-08-26
US6080571A (en) 2000-06-27
JPH10500286A (ja) 1998-01-13
GR3033268T3 (en) 2000-09-29
WO1995025789A1 (en) 1995-09-28
EP0751988B1 (de) 2000-02-09

Similar Documents

Publication Publication Date Title
DE69515028D1 (de) Die hocheffiziente herstellung und isolierung von viruspartikeln
EP1394259A3 (de) Rekombinantes infektiöses nicht-in-Segmente-geteiltes negativ-Strange-RNS-Virus
AU7007491A (en) Cdna corresponding to the genome of negative-strand rna viruses, and process for the production of infectious negative-strand rna viruses
DE69835294D1 (de) Methode zur in vitro auseinander- und wiederzusammensetzung von papillomavirus virus-ähnlichen tielchen (vlps)
AU7335196A (en) (-)-strand rna virus vector having autonomously replicating activity
PT787200E (pt) Adenovirus melhorado e metodos para a sua utilizacao
DK0923592T3 (da) Fremgangsmåder til rensning af nukleinsyrer
DE69638196D1 (de) Rekombinantes sendai-virus
HUP0001271A1 (hu) Eljárás rekombináns adenovírusok előállítására
FR2465508B1 (fr) Membranes poreuses contenant du polyacrylonitrile modifie, pour l'ultrafiltration, procede de preparation de celles-ci et applications desdites membranes
DE60233061D1 (de) Alphavirus replikon-vektorsysteme
TR199901840T2 (xx) DNA'nın cross-flow-filtrasyonu ile temizlenmesi.
PT88178A (pt) Metodo para a purificacao de virus da hepatite a
YU78402A (sh) Hemostatički aktivni preparat koji sadrži vwf i postupak njegovog pripremanja
ES8608581A1 (es) Un metodo para la construccion de un gen sintetico para pro-teina objetivo viral
DE69324645D1 (de) Verfahren zur Herstellung von Hepatitis Antigenen und Impfstoffen
CA2096888A1 (en) Process for the inactivation of viruses in preparations of proteins
DE69103798D1 (de) Katalysatorsystem und -verfahren zur selektiven Herstellung von Isoprenyl-Alkylethern aus Isopren.
DK78990A (da) Fremgangsmaade til rensning af ydre membran protein for haemophilus influenza
FI953141A0 (fi) Menetelmä soluissa tuotettavan HIV:n glykoproteiinin GP 160 eristämiseksi ja puhdistamiseksi
FR2509630B1 (fr) Procede pour eliminer des impuretes, notamment le potassium, des catalyseurs usages d'argent pour la production d'oxyde d'ethylene
CA2154854A1 (en) Immortalized lymphocytes for production of viral-free proteins
ATE55257T1 (de) Verfahren zur herstellung von hochgereinigten, hepatitis-b-virus-infektionsfreien gammaglobulinen.
PT82505A (fr) Cellules hybrides productrices d'un antigene caracteristique du virus de l'hepatite b obtenu a partir d'hepatocytes et de cellules etablies de singe procede pour l'obtention de ces cellules hybrides et application de celles-ci a la production de l'ant-gene susdit
FI98466C (fi) FSME-viruksen läntisen alatyypin eristettyjä DNA- ja RNA-molekyylejä, näitä sisältäviä vektoreita ja soluviljelmiä sekä menetelmä näiden koodittamien peptidien valmistamiseksi

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee